Domov › Nemalobunkový karcinóm pľúc › Virginia › Richmond
Klinické štúdie Nemalobunkový karcinóm pľúc v meste Richmond, VA
25 štúdií pre Nemalobunkový karcinóm pľúc hľadá účastníkov v zariadeniach v meste Richmond a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Prebieha náborFáza 3
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Prebieha náborFáza 3
- VCU Health Adult Outpatient Pavillion ( Site 0193), Richmond
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Prebieha náborFáza 3
- Virginia Cancer Institute, Richmond
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Prebieha náborFáza 3
- Local Institution - 0337, Richmond
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Prebieha náborFáza 3
- VCU Medical Center Gateway Building, Richmond
- Virginia Commonwealth University, Richmond
- VCU Health Short Pump Pavilion, Richmond
- a 4 ďalších
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Prebieha náborFáza 1/2
- VCU Medical Center Gateway Building, Richmond
- Virginia Commonwealth University, Richmond
- VCU Health Stony Point, Richmond
- a 2 ďalších
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Prebieha náborFáza 3
- VCU Health Adult Outpatient Pavillion, Richmond
Pan-tumor MRD Study
Prebieha náborObservačná štúdia
- Virginia Cancer Institute, Richmond
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Prebieha náborFáza 3
- Research Site, Richmond
- Research Site, Midlothian · 11 míľ odtiaľ
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Prebieha náborFáza 2/3
- VCU Massey Cancer Center, Richmond
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Prebieha náborFáza 2/3
- Virginia Commonwealth University (Vcu), Richmond
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Prebieha náborFáza 3
- Clinical Study Site, Richmond
- Clinical Study Site, Richmond
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Prebieha náborFáza 2/3
- Virginia Cancer Institute - West End, Richmond
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Prebieha náborFáza 3
- VCU Health Adult Outpatient Pavillion, Richmond
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Prebieha náborFáza 3
- Research Site, Midlothian · 11 míľ odtiaľ
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Prebieha náborFáza 3
- Virginia Commonwealth University, Richmond
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Prebieha náborFáza 3
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Prebieha náborFáza 2
- VCU Medical Center (Virginia Commonwealth University), Richmond
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
Prebieha náborFáza 2
- Virginia Commonwealth University, Richmond
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Prebieha náborFáza 2
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Prebieha náborFáza 2/3
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Prebieha náborFáza 2
- Virginia Commonwealth University, Richmond
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Prebieha náborFáza 2
- Virginia Commonwealth University, Richmond
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Prebieha náborObservačná štúdia
- VCU Massey Cancer Center at Stony Point, Richmond
- Virginia Commonwealth University/Massey Cancer Center, Richmond
Repositioning Immunotherapy in VetArans With Lung Cancer
Prebieha náborFáza 2
- Richmond VA Medical Center, Richmond, VA, Richmond
Štúdie Nemalobunkový karcinóm pľúc v iných mestách
- Houston, TX145 štúdií
- New York City, NY121 štúdií
- Arlington, VA104 štúdií
- Nashville, TN97 štúdií
- Boston, MA90 štúdií
- Los Angeles, CA87 štúdií
- St. Louis, MO73 štúdií
- Chicago, IL61 štúdií
- Baltimore, MD60 štúdií
- San Antonio, TX59 štúdií
- Columbus, OH57 štúdií
- Washington, DC55 štúdií
Iné štúdie v Richmond
- Rakovina prsníka26 štúdií
- Rakovina prostaty19 štúdií
- Srdcové zlyhanie16 štúdií
- Rakovina pľúc14 štúdií
- Kardiovaskulárne ochorenia13 štúdií
- Kolorektálny karcinóm13 štúdií
- Steatotické ochorenie pečene12 štúdií
- Akútna myeloidná leukémia12 štúdií
- Metastatická rakovina12 štúdií
- Skvamóznocelulárny karcinóm hlavy a krku12 štúdií
- Melanóm11 štúdií
- Obézita11 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.